Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $78.00 Consensus Target Price from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $78.00.

LNTH has been the topic of several recent research reports. Truist Financial increased their price objective on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Mizuho upped their target price on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th.

Lantheus Stock Up 0.9%

Lantheus stock opened at $73.87 on Wednesday. Lantheus has a one year low of $47.25 and a one year high of $111.29. The stock has a fifty day moving average of $67.24 and a 200 day moving average of $59.55. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. The stock has a market cap of $4.90 billion, a PE ratio of 31.04 and a beta of -0.08.

Institutional Trading of Lantheus

Several hedge funds have recently bought and sold shares of the stock. M&T Bank Corp bought a new position in shares of Lantheus in the fourth quarter worth about $370,950,000. Farallon Capital Management LLC increased its holdings in Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after acquiring an additional 1,950,252 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Lantheus in the 3rd quarter worth approximately $65,654,000. Norges Bank bought a new stake in Lantheus during the 4th quarter worth approximately $76,197,000. Finally, Polaris Capital Management LLC purchased a new position in Lantheus during the third quarter valued at approximately $32,687,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.